Antimicrobial Resistance: A Growing Global Health Challenge and What Can Be Done
Why antimicrobial resistance matters
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, or parasites evolve to survive medicines that once killed them.
This reduces the effectiveness of treatments, raises healthcare costs, and increases the risk of complications from routine procedures and infections. AMR affects every country and undermines progress across maternal and child health, surgery, cancer care, and infectious disease control.
Key drivers of resistance
– Overuse and misuse of antibiotics in humans: unnecessary prescriptions, incorrect dosing, and unfinished courses create selective pressure for resistant strains.
– Inappropriate use in agriculture and aquaculture: antibiotics used for growth promotion or routine prevention in animals contribute to resistant bacteria that can spread to people.
– Poor infection prevention and control: inadequate hygiene, sanitation, and vaccination enable resistant pathogens to spread in communities and healthcare settings.
– Lack of rapid diagnostics: without point-of-care tests to distinguish bacterial from viral infections, clinicians may prescribe antibiotics “just in case.”
– Insufficient new drug development: economic and scientific barriers mean fewer new antimicrobials reach the market, limiting options against resistant pathogens.
Health and economic impacts
AMR increases illness severity, hospital stays, and healthcare costs. It can turn treatable infections into life-threatening emergencies and complicate routine medical procedures that rely on effective antimicrobials. Economies also suffer due to lost productivity and higher care expenses, with vulnerable populations bearing the greatest burden.
Strategies to combat AMR
A multifaceted, coordinated response across sectors—the One Health approach—is essential. Effective strategies include:
– Strengthening stewardship programs
– Implement antibiotic stewardship in hospitals and clinics to guide appropriate prescribing.
– Educate clinicians and patients about when antibiotics are necessary and the dangers of misuse.
– Improving surveillance and data sharing
– Expand laboratory capacity for monitoring resistance patterns.
– Share surveillance data across regions to detect emerging threats and guide policy.
– Boosting infection prevention and control (IPC)
– Invest in water, sanitation, hygiene (WASH), and vaccination to reduce infection rates.
– Enforce IPC protocols in healthcare settings, including hand hygiene and sterilization practices.
– Promoting diagnostics and innovation
– Support point-of-care diagnostics to reduce empirical antibiotic use.
– Incentivize research and development for new antimicrobials, alternative therapies, and rapid tests.
– Regulating antibiotic use in animals
– Phase out medically important antibiotics for growth promotion.
– Promote veterinary stewardship and better farm management practices that reduce reliance on antimicrobials.
– Building public awareness
– Run clear, culturally appropriate campaigns to inform communities about AMR risks and responsible medicine use.
– Engage pharmacists and community health workers as trusted sources of advice.
What individuals can do
– Use antibiotics only when prescribed by a qualified professional.
– Complete the full course exactly as directed and never share antibiotics.
– Practice good hygiene, get recommended vaccinations, and prepare food safely to reduce infection risk.
– Avoid pressuring clinicians for antibiotics for viral illnesses like colds or viral bronchitis.
Policy priorities for leaders
Policymakers should prioritize funding for surveillance, stewardship, and R&D incentives; stricter regulation of antibiotic use in agriculture; and cross-sector coordination mechanisms.
Investing in health systems strengthening—especially laboratory networks, primary care, and WASH infrastructure—yields durable gains against AMR.
A collective responsibility
AMR is not confined to hospitals or borders. Combating it requires coordinated action across healthcare, agriculture, industry, and communities. By combining smarter use of existing medicines with stronger prevention, better diagnostics, and sustained investment in innovation, the global community can preserve antimicrobial effectiveness and protect public health for generations to come.